The firm is maintaining its full-year guidance and expects to make the acquisition once Lex Diagnostics obtains 510(k) clearance of its system.

The agency accused the Germany-based firm of selling multiple saliva-based ELISAs without appropriate marketing authorizations, among other violations.

The deals cover development and commercialization of next-generation sequencing and digital PCR assays for minimal residual disease detection.

The BLIPI test device was used to monitor babies' immune status from a drop of whole blood and detected sepsis within 15 minutes, enabling incubator-side testing.

Northwestern Medical will begin using PathAI's AISight digital pathology image management system as part of the deal.

Last week, readers were most interested in a story about what's up Roche's sleeve as it talked about its plans during its investor day.

Of the 30 companies included in the list, 15 saw their stock prices decline, while 15 saw their share prices rise.

The RiskReveal assay was used to determine which early-stage non-squamous NSCLC patients should undergo adjuvant chemotherapy.

The firm touted new assays, provided an update on its nanopore sequencer, and offered insights into upcoming pipeline ...

The company's flagship assay uses whole-genome sequencing to identify patients with high-risk multiple myeloma and determine which patients won't respond to therapies.

The firm's diagnostics and life sciences revenues jumped 8 percent, and Agilent raised its full-year guidance on expectations of 3 to 5 percent growth.